Melatonin: A frustrated hope in the acute phase of the COVID-19 pandemic, a therapeutic possibility in prolonged COVID
Melatonin is particularly effective in reducing symptomatology of SARS-CoV-2 infection due to its roles as an antioxidant, anti-inflammatory, and immunomodulatory agent. Melatonin is also an effective chronobiotic/hypnotic medication for treating delirium and restoring circadian imbalance in COVID p...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Asociación de Medicina del Estrés y Psicoinmunoneuroendocrinología
2023
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/pinelatam/article/view/39717 |
| Aporte de: |
| Sumario: | Melatonin is particularly effective in reducing symptomatology of SARS-CoV-2 infection due to its roles as an antioxidant, anti-inflammatory, and immunomodulatory agent. Melatonin is also an effective chronobiotic/hypnotic medication for treating delirium and restoring circadian imbalance in COVID patients in the intensive care unit. Furthermore, as a cytoprotectant, melatonin helps to prevent a number of comorbidities of COVID-19, such as diabetes, metabolic syndrome, and ischemic and non-ischemic cardiovascular diseases. The clinical sequelae and symptoms of many patients with COVID-19 can persist for months beyond the acute stage of SARS-CoV-2 infection, the so-called “long COVID”. Melatonin, as a neuroprotective agent, emerges as an excellent agent to control cognitive impairment ("brain fog") and pain in myalgic encephalomyelitis/chronic fatigue syndrome, like that documented in prolonged COVID. |
|---|